Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givosiran OLE in Acute Intermittent Porphyria
NCT02949830Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Nov 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of givosiran in acute intermittent porphyria (AIP), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percentage of Participants With Adverse Events (AEs) at Month 49. Started Oct 2016; status: completed.
02
Drugs
givosiran
03
Conditions
acute intermittent porphyria (AIP)
Beyond the preview
Go deeper on NCT02949830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949830.